| 000 | 01880 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516043010.0 | ||
| 264 | 0 | _c20111026 | |
| 008 | 201110s 0 0 eng d | ||
| 022 | _a2040-2058 | ||
| 024 | 7 |
_a10.3851/IMP1802 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBonora, Stefano | |
| 245 | 0 | 0 |
_aPharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. _h[electronic resource] |
| 260 |
_bAntiviral therapy _c2011 |
||
| 300 |
_a499-504 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdenine _xadministration & dosage |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 | _aAtazanavir Sulfate |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEmtricitabine |
| 650 | 0 | 4 |
_aHIV Seropositivity _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOligopeptides _xadministration & dosage |
| 650 | 0 | 4 |
_aOrganophosphonates _xadministration & dosage |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aTenofovir |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGonzalez de Requena, Daniel | |
| 700 | 1 | _aD'Avolio, Antonio | |
| 700 | 1 | _aCalcagno, Andrea | |
| 700 | 1 | _aTettoni, Mariacristina | |
| 700 | 1 | _aSiccardi, Marco | |
| 700 | 1 | _aBaietto, Lorena | |
| 700 | 1 | _aSimiele, Marco | |
| 700 | 1 | _aTrentini, Laura | |
| 700 | 1 | _aDi Perri, Giovanni | |
| 773 | 0 |
_tAntiviral therapy _gvol. 16 _gno. 4 _gp. 499-504 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3851/IMP1802 _zAvailable from publisher's website |
| 999 |
_c20939975 _d20939975 |
||